Physician profile
Mark Baravik
NPI 1033547252
$4,986.18
in general payments reported to CMS, 2019-2025
37 companies · $1,791 in 2025
The $1,791 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $996 · 2022: $712 · 2023: $641 · 2024: $846 · 2025: $1,791.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,278.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,278.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $661.00 | 2021-2025 | Repatha, Otezla, Repatha |
| Astrazeneca Pharmaceuticals Lp | $583.80 | 2024-2025 | Breztri, Airsupra, Farxiga |
| Novartis Pharmaceuticals Corporation | $499.74 | 2021-2024 | |
| Abbvie INC. | $451.27 | 2021-2025 | |
| Novo Nordisk INC | $294.31 | 2021-2025 | |
| Lilly USA, LLC | $292.54 | 2021-2025 | Zepbound, Mounjaro, Kisunla |
| Amarin Pharma, INC. | $276.05 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $255.80 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $195.75 | 2024-2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $192.74 | 2021-2025 | Jardiance |
| Eisai INC. | $168.44 | 2021-2025 | |
| Aimmune Therapeutics, INC. | $162.67 | 2024-2025 | Zenpep |
| Esperion Therapeutics, INC. | $108.02 | 2021-2025 | Nexletol |
| Lundbeck LLC | $98.09 | 2024-2025 | Rexulti |
| Exact Sciences Corporation | $95.61 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Baravik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.